"2- Aminated Methylene Or 2- Esterified Methylene Tanshinone Derivatives, and Preparation Method and Application Thereof" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors Xu, Rongzhen; Rong, Frank; Xie, Fuwen; Lai, Hongxi, filed on November 30, 2012, was made availa
AB Science SA, a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors, announces that its phase 2 with masitinib in relapsed or refractory peripheral T-cell lymphoma was accelerated into a phase 3 randomized controlled trial. The decision to accelerate the phase 2 into phase 3 was based on the obs
Acasti Pharma Inc., an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, today announced its slate of director nominees for election at its next Annual and Special Meetin
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced it will participate in the following upcoming investor conferences. Live audio webcasts will be available on the Events and...
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in the Jefferies 2015 Healthcare Conference in New York City. Marc Beer, Chief Executive Officer of Aegerion, is...
IRVINE, Calif.& BEDMINSTER, N.J.& RESEARCH TRIANGLE PARK, N.C. Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that Vicente Anido, Jr., Ph.D., Chi
Anthera Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs, announced today that Paul F. Truex, President and Chief Executive Officer, will present a corporate update at the 2015 Annual Jefferies Healthcare Conference.
Aspyrian Therapeutics Inc. Announces FDA Acceptance of an Investigational New Drug Application for RM-1929, a First-in-Class, Precision-Targeted Therapy for Cancer. By a News Reporter-Staff News Editor at Biotech Week Aspyrian Therapeutics Inc., a drug development company creating precision-targeted therapies to treat cancer based on its...
Atossa Genetics Inc. today announced that Dr. Steven C. Quay, M.D., Ph.D., President and CEO, commented, " Dr. Engley has over 20 years of pharmaceutical industry and managed care/hospital pharmacy experience at leading companies, including The Medicines Company, ZymoGenetics, A Bristol-Myers Squibb Company, and Berlex Laboratories. Dr. Engley then
Chinese pharmaceutical authorities require that when conducting the research and development of biosimilar products in China, the applicant of biosimilar registration application and its sponsor should be in compliance with the Guidance and follow the pathway of license approval of biosimilars. How to grasp the opportunity to smoothly conduct the..
This is first time in history, Chinese pharmaceutical authorities officially issued a guidance on international multi-center clinical trials of drugs in China, which has begun to be implemented on March 1, 2015. Latest Regulations on Pharmaceutical International Multi-Center Clinical Trials in China provided a comprehensive and thorough knowledge o
Escalating cancer incidences have made the investigators to come forth with therapeutics that could reduce high morbidity and mortality rates. Cancer segment has several products belonging to different categories having different pharmacological efficacy. Food and Drug Administration is taking effective measures to offer better medical care to...
BriaCell Therapeutics Corp, an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to announce that it has just signed an LOI outlining a Manufacturing Partnership with Washington University in St. Louis and its Siteman Comprehensive Cancer Center. The proposed Manufacturing Partnership outlines terms...
Calimmune Inc., a clinical-stage gene therapy company, has successfully completed its $15 million Series B financing round, led by a large pharmaceutical company. Alexandria Venture Investments also joined with existing investors including RA Capital Healthcare Fund LP and Translational Accelerator LLC. Proceeds will be used to progress the company
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the Company will be presenting at the Jefferies 2015 Healthcare Conference, in New York. Patrick J. McEnany, Catalyst's Chief Executive Officer and Steven Mille
Cheetah Medical, a privately held and rapidly growing medical device company, announced today that it has expanded its product line and is now offering the FDA- cleared and CE-marked Starling? SV a noninvasive hemodynamic monitoring system that provides data for real-time clinical decision-making and optimized patient outcomes across a hospita
Collegium Pharmaceutical, Inc. announced today that the Company's Chairman and CEO, Michael Heffernan, will present at the Jefferies 2015 Healthcare Conference in New York City. The presentation is scheduled for Monday, June 1, 2015 at 1:30pm Eastern Time. CONTACT: Investor Contact: Doug Carlson Vice President, Corporate Development.
Concert Pharmaceuticals, Inc. today announced that it will present a corporate overview at the following upcoming investor conferences:. Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform to create novel small molecule drugs. Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc....
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced an upcoming poster presentation regarding its lead drug candidate, aldoxorubicin, at the 2015 American Society of Clinical Oncology Annual Meeting, which is being held May 29- June 2, 2015 in Chicago. Based on this data, we are allowe
VANCOUVER, British Columbia and MENLO PARK, Calif., May 27, 2015/ PRNewswire/ DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it will be presenting at several upcoming investor and scientific conferences. DelMar's data.
DGAP-News: MOLOGEN AG/ Key word: Conference MOLOGEN AG to present poster at ASCO Annual Meeting 27.05. 2015/ 09:57- PRESS RELEASE N 08/ 2015 of 05/27/2015 MOLOGEN AG to present poster at ASCO Annual Meeting Berlin, May 27, 2015- The biotechnology company MOLOGEN AG will present a
Although the FDA continues to do their best to police the sale of dangerous and, sometimes illegal, diet products, the online market is simply too vast to prevent all fraudulent companies in a timely manner. For this reason, the FDA encourages consumers to pay strict attention to the validity of products, to investigate the company and its reputati
Frank Chae, Chief of Bariatric Surgery at Sky Ridge Medical Center, is among one of the first physicians in the country certified in implanting the VBLOC vagal blocking therapy for the treatment of obesity. On January 14, 2015, EnteroMedics Inc. announced that the U.S. Food and Drug Administration approved VBLOC vagal blocking therapy, delive
REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced the appointment of Jerry Karabelas, Ph.D., to its board of directors. Dr. Karabelas has held a number of senior executive positions in major pharmaceutical companies, including Head of Healthcare and CEO of Worldwide Pharmaceuticals for Novartis AG, where he had full
The Spectranetics Corporation today announced that 12- month data from the EXCITE ISR clinical trial were presented by Craig Walker, MD, at New Cardiovascular Horizons in New Orleans. Results of the landmark study show that Spectranetics' laser atherectomy devices used with PTA, are safer and more effective than PTA alone for treating femoropopli